Collaborators

Precision Biologics is committed to the discovery, development and commercialization of novel cancer therapeutics and diagnostics. Precision Biologics has active collaborations with a growing number of organizations, among them:


Clinical Trials

Duke University Medical Center
National Cancer Institute
University of Texas Southwestern Medical Center
Einstein/Montefiore Medical Center
Rutgers-Cancer Institute of New Jersey
Moffitt Cancer Center
Washington University St. Louis
Johns Hopkins Hospital
Dana Farber Cancer Institute
Beth Israel Deaconess
Massachusetts General Institute
Yale Cancer Center
Sydney Kimmel Cancer Center at Thomas Jefferson University

Scientific Research

Duke University Medical Center
National Cancer Institute
University of Texas Southwestern Medical Center
Einstein/Montefiore Medical Center
North Shore – LIJ Health System

Commercial Partners

Cytovance Biologics
Almac Clinical Services
Catalent, Inc

To inquire about potential partnerships or collaboration, please contact: info@precision-biologics.com

“Our monoclonal antibodies have the ability to act as a companion diagnostic platform to our therapeutic program by recognizing the tumor specific antigen that our therapeutic antibody targets and determine which patients are a candidate to receive treatment.”

Philip M Arlen, MD

Chief Executive Officer